Tazverik (tazemetostat) — United Healthcare
epithelioid sarcoma
Initial criteria
- Diagnosis of epithelioid sarcoma
- Disease is one of the following: metastatic OR locally advanced
- Disease is not eligible for complete resection
Reauthorization criteria
- Patient does not show evidence of progressive disease while on Tazverik therapy
Approval duration
12 months